Key Takeaways
- Pharma companies should shift from viewing product launches as an endpoint to treating them as the beginning of an iterative process guided by roadmaps, feedback, and communication.
- Successful iteration requires flexible roadmaps, structured feedback loops, and the ability to pivot quickly when market realities don’t align with initial assumptions.
- Clear communication across cross-functional teams—explaining assumptions, new insights, and pivots—helps organizations adapt rapidly and turn challenges into coordinated solutions.
I have argued that more pharma companies need to move away from one-shot product launches and think instead in terms of product iteration. Product launches exhaust huge amounts of time and capital—and too often disappoint. That’s in part because invariably the market doesn’t respond exactly as anticipated, and the company isn’t agile enough to quickly pivot and evolve, because they’ve been so focused on the launch.
Once you buy into the idea that launches aren’t the end stage, they’re just the beginning of a longer journey—then the question becomes: what are the keys to successful product iteration? In my experience, having worked on iteration cycles for multiple products, there are three critical components: the roadmap, the feedback, and the communication.
The real-world impact of this philosophy became clear to me during the launch of a new women's health therapy, where our approach to iteration was tested—and ultimately, changed our trajectory.
A product roadmap is more than a checklist
The product roadmap is often seen as a master plan—a sequential list of features and improvements that will roll out after the minimum viable product (MVP) hits the market. In practice, however, the roadmap can become rigid, ossified by the very process meant to make it adaptable. Teams tend to fill the next version (say, v1.1) with everything that didn’t make the MVP cut, treating it as a fixed to-do list rather than a living document responsive to market realities.
This approach misses the core purpose of iteration: to adapt based on real-world user feedback. If the roadmap is locked before the MVP even reaches customers, organizations risk missing critical market signals. The result is a disconnect between what’s planned and what’s actually needed, especially when commercial and development teams operate in silos.
Making room for the unknown
The heart of successful product iteration lies in how feedback is gathered and acted upon. In our launch of a therapy for women’s health, we learned that real-world feedback doesn’t always align with initial assumptions based on a target product profile—and it rarely arrives on a predictable schedule. For example, we assumed our product’s once-daily dosing would be its main competitive advantage over a twice-daily alternative. But once in the market, we discovered that physicians weren’t comparing us to our direct competitor at all. Instead, they were handing out samples of oral contraceptives that were not designed to treat the disease state—which was creating an entirely different benchmark. Patients were faced with the choice of seeking coverage for our product (at least at the outset) or getting free samples of the other. The choice was pretty easy for them.
